Jaguar Health (JAGX) EBIT Margin (2015 - 2026)

Jaguar Health (JAGX) has 12 years of EBIT Margin data on file, last reported at 50.23% in Q1 2026.

• On a quarterly basis, EBIT Margin rose 47575.0% year-over-year to 50.23% in Q1 2026; TTM through Mar 2026 was 88.96%, a 18837.0% increase from a year earlier, with the FY2025 full-year figure at 398.82%, down 13506.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 50.23%, up from 656.63% in the prior quarter.
• Over the last five years, EBIT Margin for JAGX reached as high as 50.23% in Q1 2026 and fell as low as 58770.0% in Q1 2022.
• Historically, EBIT Margin has averaged 6140.83% across 5 years, with a median of 312.37% in 2023.
• Across the five-year window, EBIT Margin plunged 5804434 bps in 2022 and soared 3689222 bps in 2023, its largest moves.
• Year by year, EBIT Margin stood at 19643.75% in 2022, then surged by 98 bps to 328.57% in 2023, then increased by 29 bps to 232.46% in 2024, then slumped by 182 bps to 656.63% in 2025, then jumped by 108 bps to 50.23% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 50.23% in Q1 2026, 656.63% in Q4 2025, and 234.77% in Q3 2025.